2024 Glaucoma Pharmaceuticals Market Report: Global Analysis for 2023 to 2029, May, 2024

The “2024 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2029 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook.

This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope’s eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader’s understanding of this ophthalmic segment. Coverage includes:

• Types of glaucoma and risk factors.
• Diagnosis and treatment of the disease.
• A global view of glaucoma care providers, including ophthalmologists and optometrists.
• Current estimates and five-year forecasts for disease prevalence worldwide.
• Glaucoma medications in the marketplace and their mechanisms of action.
• Discussion of generic versus branded drugs and their market impact.
• The development pipeline for glaucoma pharmaceuticals.
• Profiles of companies making and marketing glaucoma medications.

2 licensing types are available for this report:

• The price of the single-user license is $8,400.
• The price of the enterprise license is $11,850 (includes supplemental Excel file with all the tables and figures in the report, and report summary slides).

Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.

SINGLE USER LICENSE

• The Single User License allows for the use of a report by a single user within one corporate location.
• The report paper copy may not be reproduced (additional paper copies available for purchase).
• Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
• Only a single copy of the publication may be printed for internal use.
• Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

• The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
• Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
• Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Purchase price includes a printable PDF file of the report (purchasing organization may print multiple copies for use within the organization).
• Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.

Pay by credit card or by invoice.